skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Analysis of Average Royalty Rates in Pharma by Phase and Therapy Area. Royalty payments are an essential component of most pharmaceutical deals. Along with upfront payments and milestones, companies are rewarded for surpassing certain developmental hurdles. A properly structured deal will achieve a balance among these financial payment types. This begs the question of what is the proper royalty rate to be paid to the product owner or originator. In order to address this, an analysis of historical royalty rates in the pharmaceutical sector was assembled using Medtrack®’s Royalty Analyzer.

Maximizing Royalty Rate Opportunities in Pharma Licensing

Medtrack®, a leading provider of pharmaceutical and commercial intelligence information, follows nearly 32,000 pharmaceutical, biotechnology and medical device companies, 124,000 drugs (including generics) spanning 2,100 indications, and 105,000 deals including partnerships. 
Maximizing Royalty Rate Opportunities in Pharma Licensing

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: